Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

MBCC: Coffee Talk: How to Best Apply PARP Inhibition Strategies to Patient Care

MBCC: Coffee Talk: How to Best Apply PARP Inhibition Strategies to Patient Care

Friday, March 8, 2019
7:00AM – 8:30AM
Breakfast and registration: 6:30 AM – 7:00 AM

Miami Beach, FL


Information pertaining to the applications of poly(ADP-ribose) polymerase (PARP) inhibitor therapy continues to emerge at a rapid pace, with multiple PARP inhibitors approved for the treatment of patients with germline BRCA-mutated, HER2-negative breast cancer. A solid understanding of the mechanistic rationale for the use of these medications can help to optimize their potential application in the treatment of your patients. Awareness of approaches that are being studied to help maximize the efficacy of these medications, while mitigating potential treatment-related adverse events, can also help to optimize patient outcomes. It can be challenging to maintain awareness of the high volume of studies that are evaluating PARP inhibitors in different lines of therapy, both as monotherapy and in combination with other treatment modalities.

To help you meet these goals, we have developed an engaging, interactive educational activity featuring the perspectives of leading experts in the management of patients with breast cancer. Our panel will address multiple topics pertaining to the use of PARP inhibitors through a case-based format that will allow for multiple opportunities of audience interaction.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Explain the mechanistic rationale for the use of PARP inhibition in the treatment of patients with breast cancer
  2. Outline key safety and efficacy data from studies of PARP inhibition in the management of patients with breast cancer
  3. Apply recent clinical data to the development of plans to mitigate adverse events associated with PARP inhibitor therapy
  4. Summarize key ongoing studies that are exploring PARP inhibitor monotherapy and combinations in different settings for patients with breast cancer

Acknowledgment of Commercial Support

This activity is supported by educational grant from AstraZeneca.

Program Chair

Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician
Breast Medicine Service and Clinical Genetic Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information



Become a Member

Forgot Password?
Calendar of Events
Filter By